Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/28/2025 | Outperform | William Blair | |
12/2/2024 | Overweight | Piper Sandler | |
7/30/2024 | $85.00 | Outperform | Wedbush |
7/22/2024 | $80.00 | Buy | H.C. Wainwright |
6/26/2024 | $85.00 | Buy | B. Riley Securities |
6/3/2024 | $60.00 → $80.00 | Outperform | Oppenheimer |
5/13/2024 | $77.00 | Outperform | RBC Capital Mkts |
3/6/2024 | $4.00 → $46.00 | Hold → Buy | Jefferies |
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
William Blair initiated coverage of Corbus Pharma with a rating of Outperform
Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight
Wedbush initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $85.00
10-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
SCHEDULE 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701 to treat metastatic cervical cancerCRB 913 SAD/MAD obesity study expected to start in March 2025$149m of cash & investments as of December 31,2024 and cash runway expected through Q3 2027 NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2024. "During the fourth quarter and into 2025, we made si
NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in the following upcoming investor conferences. B. Riley Securities Precision Oncology & Radiopharma Investor ConferenceFormat: Panel and one-on-one investor meetingsPanel Title: Unlocking the Full Potential of Nectin-4 Targeting TherapiesDate: February 28, 2025Time: 8:00 a.m. ET TD Cowen 45th Annual Health Care ConferenceFormat: Presentation and one-on-one investor meetingsDate: March 4, 2025Time: 1:50 p.m. ETWebcast: Click here Wedbush Securities Cardiometabolic Co
Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024 Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study Low levels of peripheral neuropathy and skin toxicity observed in both studies Clinical responses seen in urothelial (mUC) and cervical cancer participants in both studies First time targeting of head and neck squamous cell carcinoma (HNSCC) with CRB-701 yields multiple responses Dose optimization is underway with dosing at 2.7 mg/kg and 3.6 mg/kg Q3W NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), announced that data from it
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h
NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors. "Dr. Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our Board," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Our recent license agreement for CRB-701 has helped cement our position as a precision o